VASCEPA: NOW AVAILABLE IN A SMALLER CAPSULE

Two 1-g capsules BID with food1
Four 0.5-g capsules BID with food1
1-g and 0.5-g capsules
1-g and 0.5-g capsules
Two 1-g capsules
BID with food1
1-g and 0.5-g capsules
Or
Four 0.5-g capsules
BID with food1
1-g and 0.5-g capsules

  • The daily dose of VASCEPA (icosapent ethyl) is 4 g/d taken as two 1-g capsules or four 0.5-g capsules twice daily with food
  • Patients should be advised to swallow VASCEPA capsules whole. Do not break open, crush, dissolve, or chew VASCEPA
  • Healthcare professionals should assess lipid levels before initiating therapy and identify other causes (e.g., diabetes mellitus, hypothyroidism, alcohol intake, or medications) of high TG levels and manage as appropriate
  • Patients should also be following an appropriate lipid-lowering diet and exercise regimen before and during treatment with VASCEPA

VASCEPA is an ethyl ester of PURE EPA that achieves steady state in 14 days1-3
Table-header-BG-gradient
Absorption De-esterified; active metabolite EPA absorbed in small intestine.
Time to Cmax 5 hours
Distribution The majority of EPA circulating in plasma is incorporated in phospholipids, TG, and cholesterol esters, and <1% is present as the unesterified fatty acid. Greater than 99% of unesterified EPA is bound to plasma proteins.
Time to steady state 14 days
Metabolism EPA is mainly metabolized by the liver via beta-oxidation similar to dietary fatty acids. Beta-oxidation splits the long carbon chain of EPA into acetyl-coenzyme A, which is converted into energy via the Krebs cycle. Cytochrome P450–mediated metabolism is a minor pathway of elimination of EPA.
Excretion The total plasma clearance of EPA at steady state is 684 mL/h. The plasma elimination half-life (t1/2) of EPA is approximately 89 hours. VASCEPA does not undergo renal excretion.

Cmax, maximum plasma concentration; EPA, elcosapentaenoic acid; TG, triglyceride.

References: 1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma, Inc.; 2017. 2. Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126(7):7-18. 3. Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjects. Clin Pharmacol Drug Dev. 2013;3(2):101-108.